Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: Possible mechanisms? [4]

Acta Oncologica

Volumn 45, Issue 4, 2006, Pages 491-492

  Ugur Ural, A ^a   Avcu, Ferit ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; DOCETAXEL; EGTAZIC ACID; RAS PROTEIN; THALIDOMIDE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE DISEASE; BREAST CANCER; CANCER CELL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; LETTER; MULTIPLE MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DIPHOSPHONATES; DRUG SYNERGISM; HUMANS; IMIDAZOLES; MALE; MULTIPLE MYELOMA; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 33745094375     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860500492083     Document Type: Letter

References (12)

1. Ullen A, Lennartsson L, Harmenberg U, Hjelm-Eriksson, Kalkner KM, Lennernas B, et al. Additive/synergistic anti-tumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44:644-50.
2. Vogt U, Bielawski KP, Bosse U, Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004;12:1109-14.
3. Ural AU, Yilmaz MI, Avcu F, Pekel A, Zerman M, Nevruz O, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003;78:443-9.
4. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930-5.
5. Avcu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, Kurt B, et al. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol 2005;74:496-500.
6. Ural AU, Avcu F. Evolving therapeutic role of bisphosphonates in multiple myeloma. Br J Cancer 2005;93:267-8.
7. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
8. Ning ZQ, Murphy JJ. Calcium ionophore-induced apoptosis of human B cells is preceded by the induced expression of early response genes. Eur J Immunol 1993;23:3369-72.
9. Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005;47:31-9.
10. Ural AU, Avcu F. Bisphosphonates may potentiate radiation effects: A new approach in cancer treatment? Biochem Biophys Res Commun 2005;336:373-4.
11. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002;277:15309-16.
12. Salomo M, Jurlander J, Nielsen LB, Gimsing P. How myeloma cells escape bisphosphonate-mediated killing: Development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol 2003;122:202-10.